See more : Nikron Technologies, Inc. (NKRN) Income Statement Analysis – Financial Results
Complete financial analysis of Twist Bioscience Corporation (TWST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Twist Bioscience Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Plant Veda Foods Ltd. (PLVFF) Income Statement Analysis – Financial Results
- ECARX Holdings Inc. (ECXWW) Income Statement Analysis – Financial Results
- Elektrotim S.A. (ELT.WA) Income Statement Analysis – Financial Results
- Orpheum Property, Inc. (PLFF) Income Statement Analysis – Financial Results
- SeaChange International, Inc. (0A8G.L) Income Statement Analysis – Financial Results
Twist Bioscience Corporation (TWST)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.twistbioscience.com
About Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 312.97M | 245.11M | 203.57M | 132.33M | 90.10M | 54.39M | 25.43M | 10.77M | 2.27M |
| Cost of Revenue | 179.63M | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M | 32.19M | 24.02M | 9.42M |
| Gross Profit | 133.35M | 89.73M | 84.24M | 51.71M | 28.69M | 6.96M | -6.76M | -13.25M | -7.15M |
| Gross Profit Ratio | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% | -123.09% | -315.20% |
| Research & Development | 90.85M | 106.89M | 120.31M | 69.07M | 43.01M | 35.68M | 20.35M | 19.17M | 18.23M |
| General & Administrative | 0.00 | 186.84M | 210.55M | 133.40M | 102.07M | 78.83M | 42.55M | 25.96M | 18.07M |
| Selling & Marketing | 0.00 | 2.90M | 2.40M | 2.50M | 1.20M | 1.30M | 900.00K | 100.00K | 200.00K |
| SG&A | 218.40M | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M | 43.45M | 26.06M | 18.27M |
| Other Expenses | 44.93M | 10.26M | -1.09M | -1.37M | -182.00K | -265.00K | -121.00K | -55.00K | 73.00K |
| Operating Expenses | 354.18M | 306.89M | 333.26M | 204.97M | 146.27M | 115.81M | 63.80M | 45.23M | 36.50M |
| Cost & Expenses | 533.81M | 462.27M | 452.59M | 285.59M | 207.68M | 163.24M | 95.99M | 69.25M | 45.93M |
| Interest Income | 15.34M | 14.37M | 3.06M | 435.00K | 1.50M | 3.03M | 999.00K | 412.00K | 241.00K |
| Interest Expense | 29.00K | 5.00K | 80.00K | 367.00K | 787.00K | 1.29M | 1.31M | 905.00K | 746.00K |
| Depreciation & Amortization | 31.43M | 29.31M | 36.64M | 11.99M | 6.68M | 6.31M | 5.73M | 5.02M | 4.23M |
| EBITDA | -176.71M | -174.15M | -191.55M | -143.91M | -132.09M | -99.77M | -63.95M | -53.10M | -39.11M |
| EBITDA Ratio | -56.46% | -71.05% | -121.36% | -116.52% | -129.04% | -195.06% | -251.52% | -493.21% | -1,723.80% |
| Operating Income | -220.83M | -217.16M | -249.02M | -153.26M | -117.58M | -108.85M | -70.56M | -58.48M | -43.66M |
| Operating Income Ratio | -70.56% | -88.60% | -122.33% | -115.81% | -130.50% | -200.15% | -277.50% | -543.16% | -1,924.02% |
| Total Other Income/Expenses | 12.67M | 13.69M | 6.50M | -1.30M | 530.00K | 1.47M | -435.00K | -548.00K | -432.00K |
| Income Before Tax | -208.17M | -203.47M | -228.27M | -154.03M | -139.55M | -107.38M | -70.99M | -59.03M | -44.09M |
| Income Before Tax Ratio | -66.51% | -83.01% | -112.14% | -116.39% | -154.88% | -197.44% | -279.21% | -548.25% | -1,943.06% |
| Income Tax Expense | 560.00K | 1.15M | -10.41M | -1.93M | 382.00K | 292.00K | 242.00K | 280.00K | 819.00K |
| Net Income | -208.73M | -204.62M | -217.86M | -152.10M | -139.93M | -107.67M | -71.24M | -59.31M | -44.09M |
| Net Income Ratio | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% | -1,943.06% |
| EPS | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| EPS Diluted | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| Weighted Avg Shares Out | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
| Weighted Avg Shares Out (Dil) | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety
Twist Bioscience to Present at Upcoming Investor Conferences
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation (TWST) Q2 2024 Earnings Call Transcript
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Source: https://incomestatements.info
Category: Stock Reports